John Sweetenham
Professor
Department of Hematology
Huntsman Cancer Institute
United States of America
Biography
John Sweetenham, MD, FRCP, FACP, is a practicing hematologist whose central clinical research interest is lymphoma and the use of stem cell transplantation. He is internationally renowned for his clinical research and has authored more than 200 original articles, chapters, and books in this area of investigation. He has been principal investigator on national and international trials in lymphoma, and is a former core committee member of the Eastern Cooperative Oncology Group Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. He also serves as Chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK. Dr. Sweetenham has been listed in “Best Doctors in America” every year since 2003, Castle Connoly’s “America’s Top Doctors,” and “America’s Top Doctors for Cancer” every year since 2009, and has recently been acknowledged by “US News Top Doctors” and Angie’s List for Healthcare.
Research Interest
Stem Cell Transplantation Lymphomas
Publications
-
Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW (2014). Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. Clin Lymphoma Myeloma Leuk, 14(3), 203-10.
-
Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R (2014). Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol, 89(4), 349-54.
-
Aronow ME, Portell CA, Sweetenham JW, Singh AD (2014). Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology, 121(1), 334-41.
